Now that treating patients with geographic atrophy (GA) is a reality, retina specialists are tasked with incorporating therapy into their practices while prioritizing patients with the highest risk of progression. Drs. Wykoff, Chang, and Goldberg share valuable tips on navigating this new era in GA.
This activity is supported by an independent medical education grant from Apellis Pharmaceuticals.
Upon completion of this activity, the participant should be able to:
Provided by Evolve Medical Education 
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Charles C. Wykoff, MD, PhD, FACS
Retina Consultants of Texas
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX
Margaret A. Chang, MD, MS
Retinal Consultants Medical Group
Sacramento, CA
Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist
Bay Area Retina Associates
Volunteer Faculty
California Pacific Medical Center
Walnut Creek, CA
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
Charles C. Wykoff, MD, PhD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Aerie Pharmaceuticals, Alcon, Annexon, Apellis Pharmaceuticals, AGTC, Arrowhead, Ascidian, Bayer, Bausch + Lomb, Boehringer Ingelheim, Cholgene, Clearside Biomedical, Curacle, Eyebiotech, EyePoint Pharmaceuticals, Foresite, Frontera, Genentech, Gyroscope, Iveric Bio, Janssen, Kato, Kiora, Kodiak Sciences, Merck, Nanoscope, Neurotech, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Ocuphire Pharma, OcuTerra, ONL, Opthea, Oxular, Palatin, PerceiveBio, Perfuse, Ray, RecensMedical, Regeneron, Regenxbio, Resonance, Roche, Sanofi, SciNeuro, Stealth, Surrozen, Suzhou Raymon, Thea Pharma, and Valo. Grant/Research Support: 4DMT, Adverum Biotechnologies, AffaMed, Alexion, Alimera Sciences, Alkahest, Allgenesis, Amgen, Annexin, Annexon, Apellis Pharmaceuticals, AsclepiX Therapeutics, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Curacle, EyePoint Pharmaceuticals, Gemini, Genentech, Gyroscope, IONIS, iRENIX, Iveric bio, Janssen, Kodiak Sciences, LMRI, McMaster University, Nanoscope, Neurotech, NGM Biopharmaceuticals, Novartis, Ocular Therapeutix, Ocuphire Pharma, OcuTerra, OliX, Ophthotech, Opthea, Oxular, Oxurion, Oyster Point, PerceiveBio, Regeneron, Regenxbio, Rezolute, Roche, SamChunDang Pharm, Sandoz, Shanghai Henlius, UNITY, Verily, and Xbrane.
Margaret A. Chang, MD, MS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Genentech, Iveric Bio, and Regenxbio. Grant/Research Support: Alexion, Allergan, Eyebio, Mylan, NGM Biopharmaceuticals, Novartis, OcuTerra, Opthea, and Regeneron.
Roger A. Goldberg, MD, MBA, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, Coherus Biosciences, EyePoint Pharmaceuticals, Genentech/Roche, Outlook, and Regeneron. Grant/Research Support: Affamed, Annexon Biosciences, Apellis Pharmaceuticals, Boehringer Ingelheim, Carl Zeiss Meditec, EyePoint Pharmaceuticals, Genentech/Roche, Janssen, Neurotech, and Novo Nordisk. Speaker's Bureau: Apellis Pharmaceuticals, Biogen, and Genentech/Roche.
The Evolve staff, planners and peer reviewer have no financial relationships with ineligible companies.
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Apellis Pharmaceuticals.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Photobiomodulation: A Non-Invasive Treatment for Ocular Disease and Trauma
1.00 program credit
Janis T. Eells, Ph.D.
Diana V. Do, MD
David Boyer, MD
David Boyer, MD
Marion Munk, MD, Ph.D
Real-World Evidence of Photobiomodulation Efficacy in Ocular Indications
1.00 program creditMarion Munk, MD, Ph.D
David Boyer, MD
